TCGA-OR-A5JF-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.232
- MYC_TARGETS_V2+0.171
- APICAL_SURFACE+0.126
- ANGIOGENESIS+0.124
- PROTEIN_SECRETION+0.104
- UNFOLDED_PROTEIN_RESPONSE+0.103
- COAGULATION+0.086
- ESTROGEN_RESPONSE_LATE+0.051
- WNT_BETA_CATENIN_SIGNALING+0.034
- PEROXISOME+0.027
Top 10 suppressed
- G2M_CHECKPOINT-0.435
- E2F_TARGETS-0.430
- MITOTIC_SPINDLE-0.382
- ALLOGRAFT_REJECTION-0.351
- INTERFERON_GAMMA_RESPONSE-0.260
- IL6_JAK_STAT3_SIGNALING-0.250
- NOTCH_SIGNALING-0.236
- INFLAMMATORY_RESPONSE-0.236
- PI3K_AKT_MTOR_SIGNALING-0.225
- INTERFERON_ALPHA_RESPONSE-0.219
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 432c57e1-e191-4fdc-9aaa-53e460c82acc | — | — | 0.763 |
| 2 | 20679021-a108-4728-ab9a-fa3ca2fed0d0 | — | — | 0.719 |
| 3 | TCGA-A2-A4S0-01A-21R-A266-07 | — | B | 0.710 |
| 4 | e3d71c3f-4e56-45fa-be88-2cf444b70a5c | — | — | 0.705 |
| 5 | MDT-AP-1115 | Med | Medulloblastoma | 0.705 |
| 6 | SRR10900550 | — | — | 0.705 |
| 7 | TCGA-78-7161-01A-11R-2039-07 | — | cohortA3 | 0.703 |
| 8 | 35c6ff25-753c-4ebe-bbe7-2e7105d052e8 | — | — | 0.701 |
| 9 | SRR8518125 | — | F | 0.701 |
| 10 | SRR25617874 | — | B | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.232 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.171 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.126 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.124 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.104 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.103 | Idelalisib | — uncovered |
| COAGULATION | 0.086 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.051 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.034 | Inavolisib | — uncovered |
| PEROXISOME | 0.027 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.027 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.014 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.013 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.004 | Inavolisib | — uncovered |